[Form 4] Adaptive Biotechnologies Corp Insider Trading Activity

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp CEO and Chairman Chad M. Robins reported open-market sales of company common stock executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 11, 2025.

He sold 83,332 shares on April 6, 2026 at a weighted average price of $14.41 per share in multiple trades between $14.19 and $14.84. He then sold 37,263 shares on April 8, 2026 at a weighted average price of $15.19 per share, with individual trades between $15.00 and $15.53.

Across both transactions, Robins sold 120,595 shares and directly held 2,180,518 shares of Adaptive Biotechnologies common stock following the most recent sale.

Insights

Equity markets analyst

CEO executes pre-planned sales totaling 120,595 shares while retaining over 2.18M shares.

The filing shows Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies, completed two open-market sales of common stock totaling 120,595 shares. Both transactions were executed under a Rule 10b5-1 trading plan adopted on August 11, 2025, indicating they were pre-scheduled rather than opportunistic.

After these sales, Robins still directly owns 2,180,518 shares, so the disposals represent a modest portion of his visible holdings. The use of a Rule 10b5-1 plan and the absence of derivative exercises suggest routine portfolio management rather than a change in his underlying equity exposure.

Insider Trade Summary 10b5-1

Net Seller: 120,595 shares ($1,766,839)

Net Sell 2 txns

Insider ROBINS CHAD M

Role CEO and Chairman

Sold 120,595 shs ($1.77M)

Type	Security	Shares	Price	Value
Sale	Common Stock	37,263	$15.19	$566K
Sale	Common Stock	83,332	$14.41	$1.20M

Holdings After Transaction: Common Stock — 2,180,518 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.19 to $14.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBINS CHAD M

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/06/2026		S(1)		83,332	D	$14.41(2)	2,217,781	D
Common Stock	04/08/2026		S(1)		37,263	D	$15.19(3)	2,180,518	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.19 to $14.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

	/s/ Chad M Robins by Kyle Piskel, Attorney-in-Fact	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)